• Prevention of acute and delayed nausea and vomiting caused by initial or repeat courses of moderately or highly emetogenic chemotherapy (moderately emetogenic chemotherapy for adults only).
• Prevention of postoperative nausea and vomiting for up to 24 hr after surgery.

Contraindicated in:

• Hypersensitivity; cross sensitivity with other 5-HT₃ antagonists may occur.

Use Cautiously in:

• OB: Safety not established in pregnancy
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Neonates <1 mo (safety and effectiveness not established).

GI: constipation, diarrhea.

Neuro: dizziness, headache.

Drug-Drug:

• Drugs that affect serotonergic neurotransmitter systems, including SSRIs, SNRIs, tricyclic antidepressants, MAO inhibitors, fentanyl, lithium, buspirone, tramadol, methylene blue, and triptans ↑ risk of serotonin syndrome

(Generic available)

• Solution for injection: 0.05 mg/mL;
• In combination with: fosnetupitant (Akynzeo); netupitant (Akynzeo); see Appendix [not included in this PDA edition].

Prevention of Chemotherapy-Induced Nausea/Vomiting

• IV (Adults): 0.25 mg given 30 min before start of chemotherapy.
• IV (Children 1 mo–<17 yr): 20 mcg/kg (max dose = 1.5 mg) given 30 min before start of chemotherapy.

Prevention of Postoperative Nausea/Vomiting

• IV (Adults): 0.075 mg given immediately before induction of anesthesia.

Aloxi

• Blocks the effects of serotonin at receptor sites (selective antagonist) located in vagal nerve terminals and in the chemoreceptor trigger zones in the CNS.

• Decreased incidence and severity of nausea and vomiting following emetogenic chemotherapy or surgery.

Therapeutic Classification: antiemetics

Pharmacologic Classification: five ht3 antagonists

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: 50% metabolized by the liver via the CYP1A2, CYP2D6, and CYP3A4 isoenzymes to inactive metabolites; 40% excreted unchanged in urine.

Half-life: 40 hr.

• Inform patient of purpose of medication.
• Advise patient to notify health care professional if nausea or vomiting occur.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

pa-lone-O-se-tron